Prader-Willi Syndrome Clinical Management and Genetic Insights

Prader-Willi syndrome is a complex neurodevelopmental disorder arising from the loss of paternally expressed genes on chromosome 15q11-q13. Clinically, infants present with profound hypotonia, feeding difficulties and failure to thrive, followed by the emergence of hyperphagia, rapid weight gain and obesity if intake is not rigorously controlled. Endocrine dysfunction is common, encompassing growth hormone deficiency, hypogonadism, central adrenal insufficiency and thyroid‐stimulating hormone deficiency. Multidisciplinary management integrates strict dietary supervision, structured behavioural strategies, growth hormone replacement to improve height, body composition and mobility, and vigilant screening for scoliosis and sleep-disordered breathing. Psychosocial support and tailored educational programmes address cognitive and behavioural challenges. Advances in genetic diagnostics have refined classification into paternal deletion, maternal uniparental disomy and imprinting-centre defects, each correlating with differential risk of psychiatric comorbidity and degree of intellectual disability. At a molecular level, loss of the SNORD116 snoRNA cluster and mutations in MAGEL2 have been implicated in dysregulation of hypothalamic neuropeptide networks governing appetite, energy balance and circadian rhythms. These insights are guiding novel therapeutic approaches—including antisense oligonucleotides, epigenetic modulators and gene-targeted interventions—aimed at correcting underlying genetic and epigenetic defects.

Research from Nature Portfolio

Mouse models lacking the SNORD116 cluster have been shown to recapitulate core features of Prader-Willi syndrome, including low birth weight, postnatal hyperphagia, increased energy expenditure and altered body composition. Detailed analyses revealed that deletion of SNORD116 leads to upregulation of neuropeptide Y in specific hypothalamic neurons, identifying a cell-type specific mechanism for appetite dysregulation. Selective ablation of SNORD116 in NPY-expressing cells reproduced the full spectrum of feeding and metabolic phenotypes, providing a foundational demonstration that targeting this non-coding RNA may restore homeostatic control of food intake in affected individuals.

Prader-Willi Syndrome Clinical Management and Genetic Insights publication trend

The graph below shows the total number of articles in prader-willi syndrome clinical management and genetic insights across all publications each year (not limited to Nature Index journals).

Technical terms

Genomic imprinting: Epigenetic phenomenon in which only one parental allele of a gene is expressed while the other is silenced.

Uniparental disomy: Genetic condition in which both copies of a chromosome are inherited from one parent, leading to abnormal imprinting.

SnoRNA: Small nucleolar RNA involved in the chemical modification and processing of other RNA molecules.

Hyperphagia: Excessive eating behaviour characterised by an insatiable appetite and rapid food consumption.

Hypotonia: Reduced muscle tone manifesting as floppiness and poor postural control in infancy.

References

1. Identifying key underlying regulatory networks and predicting targets of orphan C/D box SNORD116 snoRNAs in Prader–Willi syndrome. Nucleic Acids Research (2024).
2. Microglial phagolysosome dysfunction and altered neural communication amplify phenotypic severity in Prader-Willi Syndrome with larger deletion. Acta Neuropathologica (2024).
3. Truncated variants of MAGEL2 are involved in the etiologies of the Schaaf-Yang and Prader-Willi syndromes. American Journal of Human Genetics (2024).
4. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. Journal of Endocrinological Investigation (2015).